scholarly journals Safety and Efficacy of Tree Pollen Specific Immunotherapy on the Ultrarush Administration Schedule Method Using Purethal Trees

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Andrzej Bozek ◽  
Krzysztof Kolodziejczyk ◽  
Jerzy Jarzab
Keyword(s):  
Pollen Season ◽  
Specific Immunotherapy ◽  
Study Group ◽  
Efficacy And Safety ◽  
Tree Pollen ◽  
Analog Scale ◽  
Pollen Allergens ◽  
Similar Reduction ◽  
Administration Schedule ◽  
Nasal Symptoms

Background. Specific immunotherapy (SIT) with an ultrarush administration schedule with Purethal for tree pollen allergens has been evaluated to assess its efficacy and safety.Methods. The study group consisted of 22 patients with symptoms of allergic rhinitis and confirmed allergy to tree pollens. Patients were randomized and given an administration schedule of either ultrarush therapy or conventional preseasonal SIT. Treatment was performed during three consecutive years.Results. After three years of treatment, a similar reduction in nasal symptoms was observed; according to the visual analog scale, there was a decrease from 3.991 ± 0.804 points to 1.634 ± 0.540 in the ultrarush group and from 3.845 ± 0.265 to 1.501 ± 0.418 in the group desensitized using the conventional method (P>0.05). There was also a comparable reduction in the use of relief drugs during pollen season and an increase in the serum concentration of IgG4 to tree pollens. No significant differences in the safety profile were observed.Conclusion. An administration schedule of ultrarush SIT with Purethal Trees is a safe treatment in preliminary observations. This therapy is comparable with conventional administration of SIT in the field of efficacy and safety.

Exposure to pollen allergens in allergic rhinitis expressed by diurnal variation of airborne tree pollen in urban and rural area

2019 ◽  
Vol 74 (2) ◽  
pp. 1-6
Author(s):  
Agnieszka Lipiec ◽  
Małgorzata Puc ◽  
Aleksandra Kruczek
Keyword(s):  
Allergic Rhinitis ◽  
Diurnal Variation ◽  
Rural Area ◽  
Pollen Season ◽  
Tree Pollen ◽  
Pollen Allergens ◽  
Pollen Counts ◽  
Birch Tree ◽  
Main Pollen Season ◽  
Seasonal And Diurnal Variations

Exposure to airborne pollen allergens results in allergic symptoms in subjects who are sensitized. The paper presents diurnal variation in the counts of airborne allergenic pollen of selected trees (Betula L., Alnus Mill., Corylus L., Fagus L. and Ulmus L.) in two localities differing in the degree of urbanization: the city of Szczecin (urban) and the village of Gudowo, West Pomerania in northwest Poland (rural) in the years 2012–2014. The measurements were made by the volumetric method using a Burkardtype sampler operating in a continuous mode. The greatest similarities in the beginning of the main pollen season between the two sites studied were observed for birch and elm trees, while in the length of the main pollen season, for birch and alder trees. Pollen counts of alder and hazel reached higher levels in the rural area, while the levels of ash tree pollen counts were higher in the urban area. The level of birch tree pollen counts was similar in the two sites studied. For the majority of taxons observed in the urban and rural areas the dynamics of hourly changes in tree pollen counts were similar. The pollination peak was noted in the daytime, usually in the afternoon. For ash and elm trees increased pollen counts were observed at nighttime, while the birch tree pollen counts were at a high level for most of the 24 h cycle. The knowledge of seasonal and diurnal variations in tree pollen counts is crucial for prevention in patients with allergic rhinitis, sensitized to tree pollen allergens.

scholarly journals Clinical efficacy of subcutaneous and sublingual allergen-specific immunotherapy of allergic rhinitis and conjunctivitis

2016 ◽  
Vol 13 (6) ◽  
pp. 63-69
Author(s):  
I E Kozulina ◽  
K S Pavlova ◽  
O M Kurbacheva
Keyword(s):  
Allergic Rhinitis ◽  
Pollen Season ◽  
Specific Immunotherapy ◽  
Pharmacoeconomic Analysis ◽  
Birch Pollen ◽  
Cost Utility ◽  
Efficacy And Safety ◽  
Allergen Specific Immunotherapy ◽  
Cost Efficacy ◽  
The Cost

Objective. To evaluate the efficacy and safety of subcutaneous and sublingual allergen-specific immunotherapy (AIT), a comparative pharmaco-economic analysis. Materials and methods. The study included 60 patients with allergic rhinitis and conjunctivitis with or without asthma induced by birch pollen. In the first group patients received subcutaneous AIT (SCIT) by «Phostal - allergen of trees pollen», in the second group - sublingual AIT (SLIT) by «Staloral - allergen of birch pollen». Results. All patients after the SCIT or SLIT in the first pollen season noted a decrease in the severity of nasal and conjunctival symptoms (SMD -1,93 [95% CI -2,39; -1,47] and -1,57 [95% CI -2,39; -0,75] for groups 1 and 2, respectively) and a decrease in the rescue medication requirement (SMD -1,98 [95% CI -2,57; -1,39] and -1,86 [95% CI -2,61; -1,11] for groups 1 and 2, respectively). There were no statistically significant differences between the SCIT and SLIT efficacy. After AIT in both groups there was a significant reduction in the cost of medication and medical services (on average 5 times). In a comparative pharmacoeconomic analysis «cost/efficacy» and «cost/utility» was showed comparable results of SCIT and SLIT.

Assessment of Pain During Laser-based Procedures in the Treatment of Glaucoma

2019 ◽  
Vol 70 (6) ◽  
pp. 2105-2107
Author(s):  
Gheorghita Popa ◽  
Olimpiu L. Karancsi ◽  
Maria Alexandra Preda ◽  
Marius Cristian Suta ◽  
Lavinia Stelea ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Pain Score ◽  
The Other ◽  
Study Group ◽  
Moderate Pain ◽  
Pain Level ◽  
Analog Scale ◽  
Intense Pain ◽  
The Individual ◽  
Individual Information

Our study aimed to determine pain levels and the state of welfare connected to laser-based procedures in the treatment of patients diagnosed with uncontrolled glaucoma. The study group included 100 eyes of 100 patients diagnosed with glucoma, 50 of them being treated with micropulse transscleral laser cyclophotocoagulation, and the other 50 eyes being treated with continuous transscleral laser cyclophotocoagulation. We used visual analog scale to gather information from each patient. After analysing the individual information the following results were obtained: the pain level for the micropulse transscleral laser cyclophotocoagulation was 60.23 mm, signifying moderate pain; and the pain score for the continuous transscleral laser cyclophotocoagulation was 76.34 mm, corresponding to moderate-intense pain. Pain level generated by minimally invasive laser procedures is discussed.

Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis

2019 ◽  
Vol 19 (3) ◽  
pp. 199-209 ◽  
Author(s):  
Bing-Di Yan ◽  
Xiao-Feng Cong ◽  
Sha-Sha Zhao ◽  
Meng Ren ◽  
Zi-Ling Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Specific Immunotherapy ◽  
Meta Analysis ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung

Background and Objective: We performed this systematic review and meta-analysis to assess the efficacy and safety of antigen-specific immunotherapy (Belagenpumatucel-L, MAGE-A3, L-BLP25, and TG4010) in the treatment of patients with non-small-cell lung cancer (NSCLC). </P><P> Methods: A comprehensive literature search on PubMed, Embase, and Web of Science was conducted. Eligible studies were clinical trials of patients with NSCLC who received the antigenspecific immunotherapy. Pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated for overall survival (OS), progression-free survival (PFS). Pooled risk ratios (RRs) were calculated for overall response rate (ORR) and the incidence of adverse events. </P><P> Results: In total, six randomized controlled trials (RCTs) with 4,806 patients were included. Pooled results showed that, antigen-specific immunotherapy did not significantly prolong OS (HR=0.92, 95%CI: 0.83, 1.01; P=0.087) and PFS (HR=0.93, 95%CI: 0.85, 1.01; P=0.088), but improved ORR (RR=1.72, 95%CI: 1.11, 2.68; P=0.016). Subgroup analysis based on treatment agents showed that, tecemotide was associated with a significant improvement in OS (HR=0.85, 95%CI: 0.74, 0.99; P=0.03) and PFS (HR=0.70, 95%CI: 0.49, 0.99, P=0.044); TG4010 was associated with an improvement in PFS (HR=0.87, 95%CI: 0.75, 1.00, P=0.058). In addition, NSCLC patients who were treated with antigen-specific immunotherapy exhibited a significantly higher incidence of adverse events than those treated with other treatments (RR=1.11, 95%CI: 1.00, 1.24; P=0.046). </P><P> Conclusion: Our study demonstrated the clinical survival benefits of tecemotide and TG4010 in the treatment of NSCLC. However, these evidence might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings.

S103 – Mometasone Is Effective With or Without Oral Antihistamines

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P112-P112
Author(s):  
Joao Antonio Marta Pimentel
Keyword(s):  
Nasal Discharge ◽  
Daily Routine ◽  
Efficacy And Safety ◽  
Concomitant Therapy ◽  
Open Label ◽  
Daily Routines ◽  
Oral Antihistamine ◽  
Intranasal Corticosteroids ◽  
Nasal Symptoms ◽  
Symptom Scores

Objectives Clinical trials have demonstrated the efficacy of monotherapy with intranasal corticosteroids (INSs) for symptoms of allergic rhinitis (AR). ARIA guidelines suggest adding oral antihistamines to INS monotherapy when severe symptoms do not improve. An open-label multicenter study assessed efficacy and safety of mometasone furoate nasal spray (MFNS) alone or combined with an oral antihistamine in subjects with AR. Methods Subjects received MFNS 200 mcg QD for 56 days, with an oral antihistamine added at Day 28 or later if baseline symptoms (sneezing, nasal discharge/obstruction, tiredness, irritability) had not improved. Subjects rated individual symptom scores, daily routine and sleep limitations, and product attributes on Days 1, 28, and 56 on a scale of 0 to 10, and completed a compliance questionnaire on Day 56. Results Mean scores for AR symptoms and limitations on sleep and daily routines significantly improved from baseline to Day 28 and from Day 28 to 56 (P less than 0.001 for all). At Days 28 and 56, 47/60 and 45/56 subjects, respectively, were receiving MFNS monotherapy, and 13 required a concomitant oral antihistamine at Day 28 or later. By Day 56, symptom severity improved in 92% of subjects receiving concomitant therapy. At study end, 88% of subjects reported compliance with QD MFNS. Average product attribute scores ranged from 7.2 to 8.4. No severe adverse events were reported. Conclusions MFNS 200 mcg QD, alone or combined with an oral antihistamine, was safe and effective against AR nasal symptoms and limitations of sleep and daily activities.

Sign in / Sign up

Export Citation Format

Share Document